Carlson Investments Se

Related Party Transaction • Oct 12, 2021

EspiReport no. 29/2021Legalbasis:Article 17(1) MAR - confidential informationPublicChancellerySubject:Confidential information: Implementation of consulting agreement -support in the process of investment in a new project of Carlson ASIEvig Alfa Sp. z o.o. s.k.TheManagement Board of Carlson Investments S.A. with its registered officein Warsaw (the Company, the Issuer) informs that on 12 October 2021 itwas informed by Carlson ASI Evig Alfa Sp. z o.o. s.k. (Carlson ASI EvigAlfa) about the support of the project of Nutrix AI, a Swiss MedTechcompany.TheIssuer has identified Nutrix AI company as an entity with high potentialfor development on the international market. Carlson Investments S.A.paid special attention to the startup's innovativeness and its highsocial value, which gives Carlson ASI Evig Alfa a significantopportunity to achieve above average rate of return on investment.NutrixAI is a Swiss medical technology startup that focuses on developingartificial intelligence software and algorithms to help monitor glucosepresent in saliva and treat diabetes. The startup's ultimate goal is toharness the full potential of artificial intelligence to give patientsthe ability to monitor their health in an easy, non-invasive andpainless way. Read more at:https://nutrix.techCarlsonInvestments S.A under its agreement with Carlson Ventures InternationalLimited (CVI), which is the sole investor in Carlson ASI Evig Alfa, isentitled to receive up to 30% of the profit from the investment made byCVI through Carlson ASI Evig Alfa